June 26, 2015

Initial Phase III Data positive for CPX-351 in High Risk AML
OncLive.com – June 25

The results are encouraging because this is the third randomized study in which CPX-351 outperformed the control arm of cytarabine plus an anthracycline in overall response rate,” lead author Jeffrey Lancet, MD, senior member and chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center, said in a press release.

Therapeutic singing
Daily Commercial – June 25, 2015
“Life’s Railway” was recorded after Hamilton had finished chemotherapy from the H. Lee Moffitt Cancer Center and Research Institute in Tampa. He found the side effects from his medications made it challenging to sing as well as he wanted.

Provectus Biopharmaceuticals’ Poster Presentation Displayed on Phase 3 Study of PV-10 at 5th European Post-Chicago Melanoma / Skin Cancer Meeting
Digital Journal via Business Wire – June 25
Additionally, Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, Florida, USA) will present on PV-10 during "Symposium III - New Drugs and Trials I: Immunotherapy" to be held Thursday, June 25, from 17:40 - 17:48 (5:40PM - 5:48PM local time), also in the Royal Ballroom.

Bi-partisan Bill Encourages Personalized Cancer Care Plans for Medicare Patients
Oncology Times – June 24
…endorsed by H. Lee Moffitt Cancer Center & Research Institute

Pursuit of cash taints promise of gene tests
June 24 – New York Times
“It sounds so legitimate — who doesn’t want safe medicine?” asked Dr. Howard L. McLeod, who is medical director of the personalized medicine institute for Moffitt Cancer Center in Tampa, Fla.

New drug for lung cancer
Texomashomepage.com – June 24
Ben Creelan, MD, Assistant Faculty, Medical Oncologist at Moffitt Cancer Center in Tampa, Florida told Ivanhoe, “It’s a real game changer to be able to have a treatment which works for years in some patients.”

Local woman’s club named best in state
The Laker/Lutz News – June 24
The women prepare foods for breakfast or brunch at the Hope Lodge at the Moffitt Cancer Center.

Lion Biotechnologies to join Russell Global Index
Yahoo Finance via GlobeNewswire – June 24
TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.

Celator® Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk (Secondary) Acute Myeloid Leukemia
Yahoo Finance via PR Newswire – June 24
"The results are encouraging because this is the third randomized study in which CPX-351 outperformed the control arm of cytarabine plus an anthracycline in overall response rate," said Jeffrey Lancet, M.D., Senior Member and Chief of the Leukemia/Myelodysplasia Program at Moffitt Cancer Center and lead investigator on the Phase 3 study. 

Startup biotech companies making a big impact in cancer treatment
WNDU-NBC  – June 23
Amod Sarnaik, MD, Oncologist at Moffitt Cancer Center in Tampa, FL, added, “To see patients, like Britta, who really had a life threatening calamity actually completely reverse to normal with the help of the cell therapy is truly phenomenal.” For Britta it’s a true masterpiece.

Battling Cancer
June 23 – Upmatters.com
Amod Sarnaik, MD, Oncologist, Moffitt Cancer Center: "To see patients, like Britta, who really had a life threatening calamity actually completely reverse, you know, to normal with the help of the cell therapy is truly phenomenal." 

For patients with cancer, web-based portals can inform and empower
Oncology Nursing News – June 23
Our patients might have a greater need [for the portal] simply because of the nature of their illness,” explained Sheila Ferrall, RN, Director of Nursing Practice, Education and Clinical Effectiveness at Moffitt Cancer Center in Tampa, Florida. “I think it’s very empowering for patients to go in and look at their results.

Social media strategist loves life as a quick-change artist
The Journal Sentinel – June 22
Bruce Dierbeck, a 37-year-old account supervisor at BVK, does just that, although he admits he had no idea he would end up looking at analytics and developing strategies for Michigan State University, Moffitt Cancer Center, the Dominican Republic and others.

Life after cancer: Long-term care is lacking for psychological, emotional needs
The Ledger- June 22
"While it's a generation of information-seekers and technology-users, I don't know what's the level of awareness for somebody who had cancer when they were 10 years old and now they're 25, realizing that some of the anxiety and depression that they may be feeling at their age may be attributed to that cancer experience," said Gwendolyn P. Quinn of Moffitt Cancer Center in Tampa.

Moffitt researchers discover mechanism leading to BRAF inhibitor resistance in melanoma
Medical News Today – June 22
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant. Moffitt Cancer Center researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF.

Researchers discover novel mechanism to fight melanoma
Times of India – June 22
Moffitt Cancer Center researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF. 

Vault Nano Inc. announces Dr. Jams Mul and Dr. Antoni Ribas to join Scientific Advisory Board
TulsaCW.com via PRWEB – June 22
Dr. Mulé is the Associate Center Director for Translational Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida.

Latina women undergoing chemotherapy for breast cancer need more stress management tools
Medical News Today – June 22
Moffitt researchers and collaborators interviewed 33 Latina breast cancer patients either during focus group sessions or in-depth interviews. 

Melanoma trial begins as new cancer drugs show promise
Deccan Chronicle – June 22
Moffitt Cancer Center researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF.

Richard’s Father’s Day  Walk/Jog
Tampa Bay Times’ Things to Do – June 21
Benefits the Advanced Prostate Cancer Collaboration at Moffitt Cancer Center. Price: $25 advance, $30 day of.

Alunos fazem campanha para pagar tratamento de câncer de professora
Odia Rio – June 20
O engajamento já deu resultado: dia 4 de agosto, Berta embarca para a Flórida onde fará uma consulta no Moffitt Cancer Center.

Moffitt analysis Nivolumab Safety in melanoma patients
Melanoma News Today – June 19
During the the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center presented the results from a retrospective analysis on the safety of nivolumab in 4 ongoing phase I-III studies in patients with melanoma. 

Doctors match cancer treatment to patient's genetic makeup
Fox 13 – June 19
"She's doing fantastic. Her last scans show no evidence of disease, and I think her quality of life is excellent," said Dr. Eric Haura, Gail's oncologist at Moffitt Cancer Center.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.